HWAM
ARCT icon

Hennion & Walsh Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Hennion & Walsh Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.33M Buy
346,207
+66,528
+24% +$524K 0.07% 343
2026
Q1 		$2.16M Buy
279,679
+39,376
+16% +$287K 0.07% 328
2025
Q4 		$1.47M Buy
240,303
+161,910
+207% +$1.75M 0.05% 415
2025
Q3 		$1.44M Sell
78,393
-1,442
-2% -$23.2K 0.05% 419
2025
Q2 		$1.04M Sell
79,835
-19,419
-20% -$230K 0.04% 486
2025
Q1 		$1.05M Buy
99,254
+17,197
+21% +$273K 0.05% 462
2024
Q4 		$1.39M Buy
82,057
+47,824
+140% +$900K 0.06% 388
2024
Q3 		$795K Sell
34,233
-427
-1% -$9.13K 0.04% 507
2024
Q2 		$844K Buy
34,660
+2,730
+9% +$82.8K 0.04% 468
2024
Q1 		$1.08M Buy
31,930
+778
+2% +$27.6K 0.06% 401
2023
Q4 		$982K Sell
31,152
-23,446
-43% -$557K 0.06% 410
2023
Q3 		$1.39M Buy
54,598
+8,627
+19% +$266K 0.09% 281
2023
Q2 		$1.32M Sell
45,971
-19,545
-30% -$532K 0.08% 313
2023
Q1 		$1.57M Sell
65,516
-1,919
-3% -$34.4K 0.1% 256
2022
Q4 		$1.14M Buy
67,435
+7,072
+12% +$123K 0.07% 316
2022
Q3 		$895K Sell
60,363
-1,398
-2% -$23.5K 0.06% 351
2022
Q2 		$972K Buy
61,761
+2,376
+4% +$46.6K 0.06% 316
2022
Q1 		$1.6M Buy
59,385
+11,215
+23% +$286K 0.09% 253
2021
Q4 		$1.78M Buy
48,170
+18,157
+60% +$740K 0.09% 252
2021
Q3 		$1.43M Buy
30,013
+10,276
+52% +$460K 0.08% 285
2021
Q2 		$668K Buy
+19,737
New +$668K 0.04% 456

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Hennion & Walsh Asset Management's ARCT Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its Arcturus Therapeutics (ARCT) stake by 24% in Q2 2026, buying an estimated $524K and bringing the position to 346,207 shares worth $2.33M. The position accounts for 0.07% of the portfolio, ranked #343.

Hennion & Walsh Asset Management first reported a position in ARCT in Q2 2021 and has held it in 21 quarters since. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Hennion & Walsh Asset Management held 346,207 shares of Arcturus Therapeutics worth $2.33M as of Q2 2026.
  • Hennion & Walsh Asset Management bought 66,528 Arcturus Therapeutics shares in Q2 2026, an estimated $524K.
  • Arcturus Therapeutics made up 0.07% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #343 holding.
  • Hennion & Walsh Asset Management first reported a position in Arcturus Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.